Banco Santander S.A. Has $4.40 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Banco Santander S.A. raised its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 99.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 105,811 shares of the company’s stock after purchasing an additional 52,696 shares during the quarter. Banco Santander S.A.’s holdings in Moderna were worth $4,400,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. State Street Corp boosted its stake in Moderna by 12.1% in the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after buying an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Moderna by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after purchasing an additional 178,115 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after purchasing an additional 906,114 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Moderna by 0.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after purchasing an additional 19,819 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in Moderna by 6.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock valued at $205,431,000 after purchasing an additional 178,939 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have weighed in on MRNA. The Goldman Sachs Group cut shares of Moderna from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. Morgan Stanley decreased their price target on Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 15th. Wolfe Research started coverage on Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 price target for the company. Argus lowered Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Finally, Evercore ISI set a $50.00 target price on Moderna in a research note on Friday, February 14th. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $60.63.

Moderna Stock Up 3.8 %

NASDAQ:MRNA opened at $35.61 on Friday. Moderna, Inc. has a 12-month low of $29.25 and a 12-month high of $170.47. The stock’s fifty day simple moving average is $36.60 and its 200-day simple moving average is $49.03. The firm has a market capitalization of $13.74 billion, a P/E ratio of -3.84 and a beta of 1.86.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.